Lupin gets US FDA approval for Meloxicam

BSE : 500257	NSE: Lupin	REUTERS: LUPN.BO	BLOOMBERG: LPC IN

Mumbai, 20 July 2006: Lupin Ltd., announced today that the US FDA has approved the Company's Abbreviated New Drug Application (ANDA) for Meloxicam Tablets, 7.5 mg and 15 mg, a widely used Non-Steroidal Anti-Inflammatory Drug (NSAID). Meloxicam is indicated for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis.

Lupin's Meloxicam Tablets are the AB-rated generic equivalent of Boehringer Ingelheim's Mobic® Tablets. U.S. sales for Mobic® Tablets were approximately US$1.1 billion for the 12-month period ended December 2005 according to IMS Health.

"The approval of our Meloxicam ANDA further reinforces Lupin's ability on submitting high quality dossiers and gaining approval in time. In fact, the approval took just a little over 9 months. In addition, our thorough execution has enabled us to launch the product immediately," said Dr. Kamal K. Sharma, Managing Director, Lupin Ltd.

Lupin is among the first cluster of companies to receive ANDA approval for Meloxicam. With this approval, Lupin now has 14 ANDAs approved by the US FDA.

About Lupin
Headquartered in Mumbai, Lupin Ltd. is a leading pharmaceutical company with strong research focus. It has a programme for developing New Chemical Entities. The Company has state-of-the-art R&D center in Pune. The Company is a leading global player in Anti-TB, Cephalosporins (anti-infectives) and Cardiovascular drugs (prils and statins) and has a notable presence in the areas of diabetology, NSAIDS and Asthma.

For the financial year ended March 2006, the Company's Revenues and Profit after Tax were Rs.16,610 million (US$ 375 million) and Rs.1,827 million (US$ 41 million) respectively.

For further information contact:
Raju Kane
The Source
Tel. +91 22 24901327/28
Telefax: +91 22 24901325
Mobile: +91 98200 45656
E-mail: rajukane@sourcepr.com